WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
P.O.Box 4404 Nydalen
0403 Oslo
Norway

Visiting/delivery address:
Marcus Thranes gate 6
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New DDDs

Overview of new DDDs decided at the two previous meeting of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the DDDs from the latest meeting (temporary codes) should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the new DDD will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list.

ATC codeATC level name (INN/generic name)DDDUnit Adm.routeDeadline for objection to temporary DDDs 1) Implementation in ATC/DDD index if no objection is received
B03AB09ferric proteinsuccinylate80mgO Fe3+Final2018
A02BX14rebamipide0.3gOFinal2018
A10BF03voglibose0.6mgOFinal2018
A16AX14migalastat61.5mgOFinal2018
B01AC26vorapaxar2.08mgOFinal2018
B01AC27selexipag1.8mgOFinal2018
C09CA10fimasartan60mgOFinal2018
N04BX04opicapone50mgOFinal2018
N07XX11pitolisant18mgOFinal2018
R06AA09doxylamine25mgOFinal2018
N05AX16brexpiprazole3mgO01.09.20172018
A10BH07evogliptin5mgO01.09.20172018
N07BC05levomethadone15mgO01.09.20172018
A05AA04obeticholic acid10mgO01.09.20172018
A06AX07plecanatide3mgO01.09.20172018
J05AF13tenofovir alafenamide25mgO01.09.20172018
J01DD52ceftazidime and beta-lactamase inhibitor 2)63)PFinal2018
L03AA17pegteograstim0.3mgPFinal2018
R06AE03cyclizine0.1gP01.09.20172018
H05BX04etelcalcetide2.1mgP01.09.20172018
L04AC13ixekizumab2.9mgP01.09.20172018
L04AX03methotrexate2.5mgP01.09.20172018
R03DX08reslizumab7.5mg 4)P01.09.20172018
1) Final: indicates that the date for objection has expired
2) previous level name, ceftazidime, combinations
3) refers to ceftazidime
4) DDD remains temporary for another period

Last updated: 2017-09-07